Johnson & Johnson (JNJ) is expected to announce a 21% jump in its fourth quarter earnings on January 21, before the bell.
Analysts expect the company to post per share earnings of $2.47 in revenue of $24.16B, which translates into a 7.4% year-on-year increase.
JNJ has emerged as one of the stronger names as it moves past the Stelara loss of exclusivity, supported by solid growth across its core portfolio, JPMorgan said in its note.
The company is well-positioned to deliver over 5% sustained revenue growth, driven by mid-single-digit growth in Innovative Medicines through 2030 and a MedTech business increasingly focused on higher-growth segments, as per the brokerage. This will particularly be supported by the uptick in Tremfya growth following its approval in IBD, analysts added.
For 2026, analysts led by Elif Korkmaz have forecast topline operational growth (ex-FX) of +5.5%. Korkmaz has forecast J&J’s 2026 sales guidance at $99.5B, slightly ahead of the market’s consensus and EPS of $11.50, in line with Wall Street’s estimates.
However, Seeking Alpha analyst Mike Zaccardi has flagged risks for the company over “slower growth in its MedTech area as industry competition rises, lighter revenue gains in new products, and litigation risks that are seemingly always present with the company.”
Over the last 3 months, EPS estimates have seen 2 upward revisions and 11 downward moves, while revenue estimates have seen 5 upward revisions and 2 downward moves.
Over the last 2 years, JNJ has beaten EPS as well as revenue estimates 100% of the time, which further enhances investors’ optimism.